Rosalind Advisors’s UroGen Pharma URGN Stock Holding History

Rosalind Advisors’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-100,000	Closed	-$600K	–	47
2025 Q2	$600K	Buy	+100,000	New	+$960K	0.28%	29

Other funds holding URGN

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Rosalind Advisors's URGN Position: Q3 2025 in Review

Rosalind Advisors sold out of UroGen Pharma (URGN) in Q3 2025, closing a stake of 542,366 shares — an estimated $7.43M sold.

Rosalind Advisors first reported a position in URGN in Q4 2024 and held it in 3 quarters. The position peaked at $10.5M in Q1 2025. 161 funds tracked by Wall St. Rank hold URGN as of Q3 2025.

Rosalind Advisors reported no remaining UroGen Pharma position as of Q3 2025 after selling out during the quarter.
Rosalind Advisors sold 542,366 UroGen Pharma shares in Q3 2025, an estimated $7.43M.
Rosalind Advisors first reported a position in UroGen Pharma in Q4 2024 and held it in 3 quarters.
Rosalind Advisors's UroGen Pharma position peaked at $10.5M in Q1 2025.
161 funds tracked by Wall St. Rank held UroGen Pharma as of Q3 2025.

Based on Rosalind Advisors's 13F filing for Q3 2025, filed 13 Nov 2025.